'Thromb haemost' presentation slideshows

1.03k views • 74 slides

Quali sono gli elementi predittivi di recidiva?

520 views • 41 slides

Stephan Moll, MD University of North Carolina Chapel Hill, N.C. Dept. of Medicine, Heme-Onc smoll@med.unc Tel: 919-966-3

Venous Thromboembolism. Stephan Moll, MD University of North Carolina Chapel Hill, N.C. Dept. of Medicine, Heme-Onc smoll@med.unc.edu Tel: 919-966-3311 Richmond 9/29/2006. A. Diagnosis. Clinical assessment. D-dimer. B. Treatment. LMWH, Fondaparinux, unfract. Heparin.

836 views • 39 slides

Spotlight Case January 2006

Spotlight Case January 2006. An Ounce of Prevention. Source and Credits. This presentation is based on the Jan. 2006 AHRQ WebM&M Spotlight Case See the full article at http://webmm.ahrq.gov CME credit is available through the Web site

305 views • 30 slides

New Insights on Warfarin: How CYP 2C9 & VKORC1 Information May Improve Benefit-Risk Ratio

New Insights on Warfarin: How CYP 2C9 & VKORC1 Information May Improve Benefit-Risk Ratio . Brian F. Gage, MD, MSc Associate Professor of Medicine, Washington University in St. Louis Blood Thinner Service Medical Director, Barnes-Jewish Hospital . Overview. Cytochrome P450 (CYP) 2C9

712 views • 25 slides

Is Thromboprophylaxis Warranted in Patients with CVCs?

Is Thromboprophylaxis Warranted in Patients with CVCs?. No statistically significant difference in the risk for catheter-related thrombosis with warfarin, UFH, or LMWH vs placebo. Chaukiyal P et al. Thromb Haemost. 2008;99:38-43.

103 views • 1 slides